Akeega access in Bangladesh: the DGDA named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Bangladesh access Akeega (niraparib and abiraterone acetate) for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in adults, in combination with prednisone through the DGDA named-patient pathway, a Directorate General of Drug Administration-administered mechanism that allows a Bangladeshi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in BDT.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

Why Bangladeshi patients need Akeega through the named-patient pathway

The People's Republic of Bangladesh operates a structured pharmaceutical regulatory environment. Akeega (niraparib and abiraterone acetate) is regulated through DGDA (Directorate General of Drug Administration) channels, and a Bangladeshi family asking for Akeega is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.

Four converging patterns drive these cases. First, indication lag. Akeega's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Bangladesh or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.

In each pattern, the DGDA named-patient pathway is the mechanism that connects a Bangladeshi-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Akeega is a fixed-dose oral dual-active tablet combining the PARP inhibitor niraparib with abiraterone acetate (a CYP17A1 inhibitor), administered once daily on an empty stomach, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.

Current regulatory status of Akeega in Bangladesh

The Directorate General of Drug Administration (ঔষধ প্রশাসন অধিদপ্তর; DGDA), operating under the Ministry of Health and Family Welfare, is the national medicines regulator for Bangladesh and administers the Drugs (Control) Ordinance 1982 alongside the carried-forward Drugs Act 1940. As of 2026-05-31, no public DGDA record of a local marketing authorisation for Akeega (niraparib + abiraterone acetate, the fixed-dose combination tablet, Janssen / Johnson & Johnson) has been identified on the DGDA Registered Imported Drugs list. Single-agent abiraterone is available in Bangladesh through several local generics; the fixed-dose niraparib-abiraterone combination is not publicly documented as locally registered.

Section 14A of the Drugs (Control) Ordinance 1982 prohibits the prescription of unregistered medicines, and Section 13 requires prior DGDA approval for any drug import. Access to the Akeega combination tablet therefore proceeds as a case-by-case administrative permission under the Director General, DGDA, rather than under a statutorily named Named Patient Program (Bangladesh has not gazetted such a scheme by that name). Patient-organisation and tertiary-hospital practice typically describes this route as "Permission to Import Unregistered Medicine for Personal or Institutional Use" - this is the operational pathway, not a separate gazette entry. Source: Bangladesh Trade Portal - Registration for Foreign Medicine procedure.

Estimated turnaround for a complete DGDA file routed through a tertiary hospital pharmacy is not publicly documented by DGDA as a fixed SLA; non-emergency files lodged with the National Institute of Cancer Research and Hospital (NICRH) or BSMMU pharmacy commonly take several weeks. Customs non-commercial-import threshold of USD 7,000 (per US Department of Commerce country guide) is a customs-side threshold and is separate from the DGDA medical-import permission step.

Last DGDA bulletin observed touching imported-drug regulation: 2025-01-14 Guideline for Quality Assurance of Locally Sourced Medical Products. Last verified by ARCH-74: 2026-05-31.

Named tertiary centres in Bangladesh where Akeega is dispensed

Akeega is an oral PARP-inhibitor-plus-CYP17A1-inhibitor combination for adult medical oncology and uro-oncology. Tertiary referral in Bangladesh for BRCA-tested metastatic castration-resistant prostate cancer concentrates on the following centres:

• National Institute of Cancer Research and Hospital (NICRH), Mohakhali, Dhaka - Medical Oncology and Surgical Oncology departments; the country's sole specialised government tertiary cancer hospital and the most common DGDA permission-letter destination for unregistered oncology product.
• Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbag, Dhaka - Department of Medical Oncology and Department of Urology; university-tertiary BMT and haematology programme.
• Dhaka Medical College Hospital, Dhaka - Department of Oncology; large-volume public tertiary.
• Square Hospitals Limited, Panthapath, Dhaka - private multi-specialty tertiary; oncology and urology consultant rosters published on the hospital site.
• Evercare Hospital Dhaka (Bangabandhu Sheikh Mujib Medical University, National Institute of Cancer Research and Hospital (NICRH), Apollo Hospitals Dhaka, Square Hospital, and United Hospital), Bashundhara, Dhaka - private multi-specialty tertiary; named-patient imports are routinely filed through the in-house pharmacy.

BSMMU and NICRH publish department-head titles on their institutional sites; we cite by department rather than physician name unless the case file is in hand. Department heads at DMCH and the private centres rotate and are not consistently published.

Local pricing reference for Akeega in Bangladesh

US WAC reference for Akeega (niraparib 100 mg + abiraterone acetate 500 mg fixed-dose tablet) is in the order of USD 14,700 to USD 17,300 per 30-day supply at the FDA-labelled regimen of two tablets once daily. The reference range is taken from US WAC databases on which Janssen lists the product; the FDA label is the source of the dosing convention. Source: Akeega FDA Prescribing Information.

No public BDT (Bangladesh Taka) reference price for the Akeega combination tablet has been observed on DGDA, BSMMU, NICRH, or major-importer published price lists as of 2026-05-31; importers customarily quote BDT at the spot USD/BDT rate published by Bangladesh Bank on the day of the proforma invoice plus permit and logistics overhead. We do not estimate a BDT figure in this guide; we issue a country-specific quotation at intake with the day-of-quote spot conversion shown.

Price snapshot date: 2026-05-31. The FDA-labelled regimen requires combination with prednisone 5 mg twice daily and concurrent gonadotropin-releasing-hormone analogue therapy; both are locally available in Bangladesh and are not part of the import file.

Country-specific access barriers for Akeega in Bangladesh

The principal procedural barrier is that DGDA's import-permission letter under the 1982 Ordinance is issued case-by-case and is not bundled with a routine SLA. Each shipment requires a fresh permission letter; chronic continuous therapy (Akeega is administered until disease progression or unacceptable toxicity) requires re-application by the institutional importer per cycle. Documentation is BMDC-licensed-prescriber-stamped prescription within three months, hospital medical report supporting the BRCA-mutated mCRPC indication, patient national ID copy, supplier pro-forma invoice, and where the institutional channel is used, the hospital cover letter and pharmacy authorisation.

Bangladesh has no nationwide universal health insurance scheme as of 2026-05-31. Subsidised access at Ministry of Health and Family Welfare tertiary hospitals (NICRH, BSMMU, Dhaka Medical College Hospital) is the principal public-sector mechanism for prostate-cancer care, but the MOHFW procurement budget for novel oral combination oncologics is constrained, and Akeega is not on the locally-procured drug list. Case-by-case high-cost-medicine grants are available through the Honourable Prime Minister's Welfare Fund and the Prime Minister's Special Fund for citizens lacking means. The Shasthyo Surokhsha Karmasuchi (SSK) pilot covers below-poverty-line families in selected upazilas and does not document specialty-drug coverage for unregistered imports.

Private health insurance penetration in Bangladesh is low; group / corporate policies (Pragati Life, Delta Life, MetLife Bangladesh, Green Delta, Pioneer, Sadharan Bima Corporation) cover formal-sector employees, and coverage of unregistered named-patient imports is policy-specific and customarily subject to pre-authorisation. The dominant funding pattern for the Akeega combination in Bangladesh is patient self-pay supplemented by family savings, remittances, charitable hospital channels (Ahsania Mission Cancer & General Hospital), Prime Minister's welfare fund applications, and pharma compassionate-access enrolment where Janssen's regional programme accepts a Bangladesh-based file.

Customs handling for oral solids is comparatively straightforward; Akeega is an ambient-storage product and does not carry the cold-chain or controlled-substance overheads that complicate other oncology imports. Bangladesh's high out-of-pocket share of total health expenditure (consistently above 65% per WHO and the National Health Accounts) is the financial backdrop against which Akeega cases are typically framed.

Recent local regulatory news touching Akeega or its drug class in Bangladesh

No DGDA bulletin specifically naming Akeega, niraparib + abiraterone combination, or the PARP-inhibitor drug class has been observed in the last twelve months on the DGDA all-categories notices page as of 2026-05-31. The following adjacent regulatory developments may affect the import workflow:

• 2025-01-14 - DGDA published the Guideline for Quality Assurance of Locally Sourced Medical Products; the guideline tightens lot-by-lot QA expectations and indirectly affects how block-list approvals are processed for imported finished products. Source: DGDA Guideline PDF.
• The Government of Bangladesh has signalled a planned new medicine-regulation law to update the 1982 Ordinance; the Bill is in active consultation. The replacement statute may rename the unregistered-import administrative carve-out under which Akeega is currently imported. Source: Dhaka Tribune coverage.

What your physician needs to provide

For a Bangladeshi-licensed specialist prescribing Akeega through the DGDA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in adults, in combination with prednisone, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Akeega is the appropriate next step given a fixed-dose oral dual-active tablet combining the PARP inhibitor niraparib with abiraterone acetate (a CYP17A1 inhibitor), administered once daily on an empty stomach.

The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Akeega (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.

The treating physician's Bangladeshi license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.

Common questions about Akeega in Bangladesh

Will out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Akeega is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by DGDA? The DGDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DGDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Bangladeshi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Bangladesh Medical and Dental Council (BMDC) and the DGDA verifies the active license; the DGDA application records both the prescribing physician and the dispensing facility.

Can I receive Akeega at home? The dispensing facility must be Bangladeshi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Where Reserve Meds fits in Akeega cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DGDA, and we do not replace your dispensing pharmacy. For Akeega specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Bangladesh, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Akeega case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DGDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Bangladeshi tertiary specialty care concentrates at Square, Apollo Imperial, United, Evercare, and Labaid in Dhaka; the DGDA named-patient import authorisation is the standard mechanism for unregistered specialty medicines and is typically filed by the treating consultant at one of these centres.

Next step

If your Bangladeshi physician has prescribed Akeega and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Reserved for you.

---

Related

• Akeega drug overview
• Bangladesh country page
• Named-patient pathway overview